

DIMERIX SIGNS LICENCE AGREEMENT FOR RECEPTOR-HIT TECHNOLOGY PLATFORM

MELBOURNE, Australia, 24 June 2019: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company, announced it has licensed its proprietary Receptor-HIT assay to Excellerate Bioscience, a UK-based pharmacological assay service provider. Under the non-exclusive Agreement, Excellerate will offer Receptor-HIT to leading pharmaceutical and biotechnology companies, as well as academic institutes, as part of its world-class expertise in assay technology on which Dimerix will receive an undisclosed royalty on gross revenues of the service fee. Both companies will market the Receptor-HIT offering and Excellerate Bioscience will run the assay service from its new facility in BioCity, Nottingham UK.

The licensing of Receptor-HIT to Excellerate Bioscience further commercialises the technology on which Dimerix was originally founded, whilst Dimerix continues to concentrate on its core business of developing innovative new therapies in areas with unmet medical needs.

“Excellerate Bioscience has a reputation for excellence in the field of molecular and cellular pharmacology and they are in the best position to maximise the value of Receptor-HIT in close geographical proximity to the wider research and development community”, said Dimerix CEO, Dr Nina Webster.

Professor Kevin Pflieger, co-inventor of Receptor-HIT, Head of Molecular Endocrinology & Pharmacology at The University of Western Australia’s Centre for Medical Research and Harry Perkins Institute of Medical Research, and Chief Scientific Advisor to Dimerix, will initiate marketing of the assay service on behalf of Dimerix and Excellerate this week at the SLAS Europe 2019 conference in Barcelona.

About Receptor-HIT

Cell-based assays are important tools used by the global pharmaceutical industry in drug discovery and development. Dimerix’s patented cell-based assay, known as Receptor-HIT (Heteromer Investigation Technology), can be applied to a number of stages of the drug development process and has previously been used under licence by leading global pharmaceutical companies to profile a wide range of receptor targets. Compared with the traditional analysis of single target receptors in isolation, Receptor-HIT is able to identify differences in signalling behaviour when receptors interact as complexes, known as heteromers.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com



Receptor-HIT can be applied to receptors such as G protein-coupled receptors (GPCRs); a large and important family of drug targets that play a central role in many biological processes and are linked to a wide variety of diseases.

Dimerix's core technology platform allows characterisation of different receptors that functionally interact and result in different pharmacology when natural ligands or small molecule drugs, peptides or antibodies bind to them. This platform technology was used to identify and characterise the GPCRs targeted in Dimerix's lead clinical program, DMX-200 – allowing rapid progress from proof of concept in vitro into Phase 2 clinical trials.

About Excellerate Bioscience Limited

Excellerate Bioscience is a dynamic and innovative organisation, built on a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

Based in BioCity Nottingham UK, the company applies state of the art pharmacological theory and technology to improve the efficiency and translatability of in vitro pharmacological profiling, providing solutions to some of the world's leading pharmaceutical and biotechnology companies, as well as globally-recognised academic institutions.

The Excellerate Bioscience team has expertise in all aspects of quantitative assessment of drug-target interactions, and has pioneered the use of kinetic binding and signalling data to enhance compound selection decisions at all stages of the discovery process. Furthermore, the team has significant experience in characterising the pharmacology of novel biologics targeting GPCRs.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com



About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for kidney disease. DMX-200 has granted patents in various territories until 2032.

In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all trial endpoints were achieved. In a subsequent sub-group analysis, significant clinical efficacy signals were seen in the diabetic group.

DMX-200 administered to patients already taking irbesartan reduced proteinuria levels by a further 36%. This reduction in proteinuria is highly correlated with improved renal function and delay in kidney failure and dialysis. The compelling results from this study prompted the decision to initiate two different clinical trials in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com